Home LiteratureArticle Details
PMID: 7538813 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Full-length but not truncated CD34 inhibits hematopoietic cell differentiation of M1 cells.

Blood ·Vol. 85 ·No. 11 ·1995-06-01 ·Pages 3040-7

Fackler MJ, Krause DS, Smith OM, Civin CI, May WS

Abstract

CD34 is expressed on human and murine hematopoietic stem and progenitor cells and its clinical usefulness for isolation of stem/progenitor cells has been well established. Although expression of CD34 is regulated in a developmental stage-specific manner, the function of CD34 is not known. Recently we have shown that both a full-length and truncated form of CD34 protein is expressed by hematopoietic cells (Blood 84:691, 1994). To test whether failure to suppress either form of CD34 could affect terminal myeloid differentiation, we constitutively expressed these CD34 proteins in murine M1 myeloid leukemia cells, which can be terminally differentiated to macrophages by treatment with interleukin-6 of leukemia inhibitory factor. Surprisingly our results show that forced expression of the full-length but not the truncated form of CD34 impedes terminal differentiation by these agents. Because the difference between the two forms of CD34 protein resides in the length of their respective cytoplasmic tail domains, our findings strongly suggest that the cytoplasmic domain region of full-length CD34 is responsible for the observed maturation arrest phenotype. These findings suggest a potential negative regulatory role for full-length CD34 in hematopoietic cell differentiation and may explain, at least in part, the block in maturation observed in CD34+ acute myeloid leukemia.

MeSH Terms
Acute Disease Animals Antigens, CD/chemistry,genetics,physiology Antigens, CD34 Base Sequence Cell Differentiation/drug effects Gene Expression Regulation, Leukemic/drug effects Growth Inhibitors/pharmacology Hematopoietic Stem Cells/drug effects Interleukin-6/pharmacology Leukemia Inhibitory Factor Leukemia, Myeloid/pathology Lymphokines/pharmacology Macrophages Mice Molecular Sequence Data Peptide Fragments/genetics Phagocytosis Recombinant Fusion Proteins/chemistry,genetics,metabolism Tumor Cells, Cultured/drug effects
Chemicals
Antigens, CD Antigens, CD34 Growth Inhibitors Interleukin-6 LIF protein, human Leukemia Inhibitory Factor Lif protein, mouse Lymphokines Peptide Fragments Recombinant Fusion Proteins
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Fackler M J
Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA.
Krause D S
Smith O M
Civin C I
May W S
Article Info
Journal
Blood
Abbr.
Blood
ISSN
0006-4971
Published
1995-06-01
Pages
3040-7
Language
English
Region
United States
NLM ID
7603509
Subset
IM
Grants
NCI NIH HHS · CA44649 · United States
NCI NIH HHS · CA58492 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com